New drug for advanced solid tumors with MET, ROS1, or NTRK changes
Part of Cancer clinical trials.
This trial tests a new drug (ANS014004) for people with advanced solid tumors that have a specific gene change (MET, ROS1, or NTRK). It aims to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are able to perform daily activities with little or no help (ECOG 0-1)
- Your doctor expects you to live at least 12 more weeks
- Your cancer can be seen and measured on scans
- You have a specific gene change (MET, ROS1, or NTRK) in your tumor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This trial tests a new drug called ANS03 for people with certain genetic changes (ROS1 or NTRK) in their solid tumors. The goal is to see if ANS03 can shrink or slow the cancer.
This trial tests a new drug, VERT-002, for people with advanced solid tumors, including non-small cell lung cancer (NSCLC), that have specific changes in the MET gene. It aims to see if the drug can shrink tumors or stop them from growing when other treatments haven't worked or aren't available.
This early-phase trial tests a new drug called ASD141 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if it is safe and how well it works against the cancer.
This trial tests a new drug (ANS014004) combined with an EGFR-targeted therapy for people with advanced non-small cell lung cancer that has an EGFR mutation. It is for those whose cancer has gotten worse after standard treatments or who cannot take them.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.